DE602005010074D1 - Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer - Google Patents

Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer

Info

Publication number
DE602005010074D1
DE602005010074D1 DE602005010074T DE602005010074T DE602005010074D1 DE 602005010074 D1 DE602005010074 D1 DE 602005010074D1 DE 602005010074 T DE602005010074 T DE 602005010074T DE 602005010074 T DE602005010074 T DE 602005010074T DE 602005010074 D1 DE602005010074 D1 DE 602005010074D1
Authority
DE
Germany
Prior art keywords
pharmaceutical compositions
improved performance
polymers
hpmca
performance containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005010074T
Other languages
English (en)
Inventor
Walter Christian Babcock
Dwayne Thomas Friesen
David Keith Lyon
Warren Kenyon Miller
Daniel Tod Smithey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005010074(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602005010074D1 publication Critical patent/DE602005010074D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B13/00—Preparation of cellulose ether-esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/08—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals with hydroxylated hydrocarbon radicals; Esters, ethers, or acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/32—Cellulose ether-esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005010074T 2004-05-28 2005-05-18 Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer Expired - Fee Related DE602005010074D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57554104P 2004-05-28 2004-05-28
US58654904P 2004-07-09 2004-07-09
PCT/IB2005/001580 WO2005115330A2 (en) 2004-05-28 2005-05-18 Pharmaceutical compositions with enhanced performance

Publications (1)

Publication Number Publication Date
DE602005010074D1 true DE602005010074D1 (de) 2008-11-13

Family

ID=35451370

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010074T Expired - Fee Related DE602005010074D1 (de) 2004-05-28 2005-05-18 Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer

Country Status (8)

Country Link
US (2) US8207232B2 (de)
EP (1) EP1753402B1 (de)
JP (1) JP2008501009A (de)
AT (1) ATE409462T1 (de)
CA (1) CA2568007A1 (de)
DE (1) DE602005010074D1 (de)
MX (1) MXPA06013891A (de)
WO (1) WO2005115330A2 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
WO2009125415A1 (en) * 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
US8685458B2 (en) 2009-03-05 2014-04-01 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
ES2873502T3 (es) 2009-03-27 2021-11-03 Bend Res Inc Proceso de secado por pulverización
KR101682466B1 (ko) * 2010-02-01 2016-12-05 롯데정밀화학 주식회사 아세틸화 셀룰로오스 에테르 및 이를 포함하는 물품
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
CN103153343B (zh) * 2010-06-14 2015-02-11 陶氏环球技术有限责任公司 具有提高的醋酸酯和琥珀酸酯取代的醋酸羟丙基甲基纤维素琥珀酸酯
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
PT2611529T (pt) 2010-09-03 2019-05-09 Bend Res Inc Método de secagem por pulverização
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
KR101088845B1 (ko) * 2011-01-21 2011-12-06 원광대학교산학협력단 황금 추출물의 속효성 고체 분산체, 이를 함유한 경구용 제제 및 이들의 제조방법
MX2013010306A (es) 2011-03-08 2013-12-09 Zalicus Pharmaceuticals Ltd Formulaciones de dispersion solida y metodos de uso de las mismas.
US8409560B2 (en) 2011-03-08 2013-04-02 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
CN104245741B (zh) 2012-03-27 2017-05-24 陶氏环球技术有限责任公司 一种制备纤维素醚的酯的方法
US9320799B2 (en) 2012-04-11 2016-04-26 Dow Global Technologies Llc Esterified cellulose ethers having a specific substituent distribution
WO2013154977A1 (en) 2012-04-11 2013-10-17 Dow Global Technologies Llc Novel sustained release dosage forms
US9757465B2 (en) 2012-04-11 2017-09-12 Dow Global Technologies Llc Composition comprising an organic diluent and a cellulose ether
US9364546B2 (en) 2012-04-11 2016-06-14 Dow Global Technologies Llc Melt-extruded composition comprising a cellulose ether
JP6235584B2 (ja) 2012-07-17 2017-11-22 ダウ グローバル テクノロジーズ エルエルシー 高置換ヒドロキシアルキルメチルセルロースを含む固体分散体
BR112014031471B1 (pt) 2012-07-17 2020-12-01 Dow Global Technologies Llc composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem
CN102807625A (zh) * 2012-08-23 2012-12-05 浙江中维药业有限公司 一种醋酸羟丙甲纤维素琥珀酸酯的制备方法
US10730957B2 (en) 2012-08-24 2020-08-04 Dow Global Technologies Llc Process of preparing an esterified cellulose ether in the presence of an alkali metal carboxylate and an aliphatic carboxylic acid
BR112015002056A2 (pt) 2012-08-24 2017-07-04 Dow Global Technologies Llc éter de celulose esterificado, composição, dispersão sólida, processo para produzir a dispersão sólida, forma de dosagem e invólucro de cápsula
KR102138546B1 (ko) * 2012-08-24 2020-07-28 다우 글로벌 테크놀로지스 엘엘씨 부분적으로 가교결합된 에스테르화된 셀룰로즈 에테르
MX2015002430A (es) * 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
BR112015000073A2 (pt) 2012-08-24 2017-06-27 Dow Global Technologies Llc processo para preparar dois ou mais ésteres de um éter de celulose e processo para preparar um éter de celulose esterificado
US9737538B2 (en) * 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (de) 2013-02-12 2018-05-30 Bend Research, Inc. Feste dispersionen mit geringer wasserlöslichkeit
BR112015021179B1 (pt) 2013-03-01 2021-11-30 Hercules Incorporated Polímero para melhor desempenho de fármaco e melhor processabilidade, composição compreendendo um fármaco e um polímero e método para a produção de acetato succinato de hidroxipropilmetilcelulose
CN105025887B (zh) * 2013-03-07 2017-07-28 陶氏环球技术有限责任公司 新颖极低粘度酯化纤维素醚
EP2964679B1 (de) * 2013-03-07 2018-04-04 Dow Global Technologies LLC Neue zelluloseesterether mit niedriger viskositàt und hohem molekulargewicht
WO2014137779A1 (en) 2013-03-07 2014-09-12 Dow Global Technologies Llc Novel esterified cellulose ethers of very high molecular weight
CN105899542B (zh) 2013-03-07 2018-08-03 陶氏环球技术有限责任公司 新颖低粘度酯化纤维素醚
US9890221B2 (en) 2013-05-14 2018-02-13 Dow Global Technologies Llc Cellulose ethers esterified with dicarboxylic acid
CN104208713B (zh) * 2013-06-03 2018-04-27 信越化学工业株式会社 用于热熔挤出的组合物以及用其制备热熔挤出产品的方法
US9587037B2 (en) 2013-09-23 2017-03-07 Dow Global Technologies Llc Process for recovering an esterified cellulose ether from a reaction product mixture
JP6353061B2 (ja) 2013-09-25 2018-07-04 ダウ グローバル テクノロジーズ エルエルシー 有機液体希釈剤及び特定のヒドロキシアルキルメチルセルロースを含む組成物
BR112016003993A2 (pt) 2013-10-23 2017-09-12 Dow Global Technologies Llc método, dispositivo de computação e sistema
KR102162542B1 (ko) * 2013-12-20 2020-10-07 주식회사 다이셀 지질 대사 개선 작용을 갖는 영양 조성물
KR102286952B1 (ko) * 2013-12-31 2021-08-09 롯데정밀화학 주식회사 입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말
KR102362913B1 (ko) * 2014-02-20 2022-02-17 뉴트리션 ＆ 바이오사이언시즈 유에스에이 1, 엘엘씨 높은 분자량 및 균질성의 신규한 에스테르화된 셀룰로오스 에테르
US10300085B2 (en) * 2014-03-24 2019-05-28 Daicel Corporation Nutritional composition
GR1008554B (el) 2014-06-12 2015-09-03 ΦΑΡΜΑΤΕΝ ΑΝΩΝΥΜΟΣ ΒΙΟΜΗΧΑΝΙΚΗ ΚΑΙ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΙΑΤΡΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ με δ.τ. ΦΑΡΜΑΤΕΝ, Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου
JP7044550B2 (ja) 2014-08-27 2022-03-30 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー アセトン不溶性含有量の低いエステル化セルロースエーテル
BR112017008431A2 (pt) * 2014-10-31 2018-01-23 Dow Global Technologies Llc processo para produzir um acetato succinato éter de celulose
EP3212169B1 (de) 2014-10-31 2021-01-13 Bend Research, Inc. Verfahren zur herstellung von in einer matrix dispergierten aktiven domänen
JP2017533324A (ja) 2014-10-31 2017-11-09 ダウ グローバル テクノロジーズ エルエルシー セルロースエーテルのエステルを調製するための方法
CN107074978A (zh) 2014-10-31 2017-08-18 陶氏环球技术有限责任公司 制备纤维素醚的酯的有效方法
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
EP3242896B1 (de) 2015-01-08 2018-12-05 Dow Global Technologies LLC Verfahren zur herstellung eines wasserlöslichen cellulosederivats mit reduziertem gehalt an wasserunlöslichen partikeln
CN107428847B (zh) 2015-03-16 2018-11-16 陶氏环球技术有限责任公司 具有低中和度的水溶性酯化纤维素醚
KR20170128370A (ko) 2015-03-16 2017-11-22 다우 글로벌 테크놀로지스 엘엘씨 에스테르화된 셀룰로오스 에테르를 분별화하는 방법
EP3271404B1 (de) 2015-03-16 2019-01-09 Dow Global Technologies LLC Wasserlösliche veresterte celluloseether
MX2017011091A (es) 2015-03-16 2017-11-10 Dow Global Technologies Llc Proceso para preparar un eter de celulosa esterificado en presencia de un acido carboxilico alifatico.
KR20170128355A (ko) 2015-03-16 2017-11-22 다우 글로벌 테크놀로지스 엘엘씨 에스테르화 셀룰로오스 에테르의 겔화
US20180071396A1 (en) 2015-03-16 2018-03-15 Dow Global Technologies Llc Aqueous solution of an esterified cellulose ether
JP6737810B2 (ja) * 2015-05-15 2020-08-12 ダウ グローバル テクノロジーズ エルエルシー 高分子量のエステル化セルロースエーテルを調製するプロセス
BR112017023272A2 (pt) * 2015-05-15 2018-08-07 Dow Global Technologies Llc processo para produzir éteres de celulose esterificados de peso molecular muito elevado e baixa viscosidade
KR20180056668A (ko) 2015-09-24 2018-05-29 다우 글로벌 테크놀로지스 엘엘씨 아세트산과 반응 촉매의 존재하에서 셀룰로오스 에테르의 에스테르를 제조하기 위한 방법
US11142633B2 (en) 2015-10-02 2021-10-12 Nutrition & Biosciences Usa 1, Llc Aqueous composition comprising dispersed esterified cellulose ether
KR20180090834A (ko) 2015-12-08 2018-08-13 다우 글로벌 테크놀로지스 엘엘씨 셀룰로오스 에테르 및 수용성 에스테르화된 셀룰로오스 에테르를 포함하는 조성물
WO2017146853A1 (en) 2016-02-24 2017-08-31 Dow Global Technologies Llc Aqueous composition comprising water-soluble esterified cellulose ethers
US10604588B2 (en) * 2016-04-05 2020-03-31 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate powder excellent in dissolved state and production method thereof, and production methods for composition for solid dispersion, coating composition, drug-containing particle, and solid preparation
MX2018012557A (es) 2016-04-15 2019-07-04 Janssen Sciences Ireland Uc Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside.
KR20190013815A (ko) 2016-05-25 2019-02-11 다우 글로벌 테크놀로지스 엘엘씨 셀룰로스 에터 아세테이트의 수용액
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
WO2017223018A1 (en) 2016-06-23 2017-12-28 Dow Global Technologies Llc Esterified cellulose ethers comprising trimellityl groups
WO2017223017A2 (en) 2016-06-23 2017-12-28 Dow Global Technologies Llc Esterified cellulose ethers comprising phthalyl groups
CN106317229A (zh) * 2016-08-22 2017-01-11 四川北方硝化棉股份有限公司 一种制备低取代度醋酸纤维素的生产方法
WO2018039214A1 (en) 2016-08-23 2018-03-01 Dow Global Technologies Llc Esterified cellulose ethers comprising maleyl groups
EP3504246B1 (de) 2016-08-23 2020-07-22 Dow Global Technologies LLC Celluloseether-acetat-phthalate
KR20190069446A (ko) 2016-10-18 2019-06-19 다우 글로벌 테크놀로지스 엘엘씨 에스터화된 셀룰로스 에터를 제조하는 효율적인 공정
US10888525B2 (en) * 2016-11-02 2021-01-12 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate and method for producing the same
JP2020511566A (ja) 2017-03-17 2020-04-16 ダウ グローバル テクノロジーズ エルエルシー 反応生成物混合物からエステル化セルロースエーテルを回収する方法
EP3596131B1 (de) 2017-03-17 2021-05-05 Nutrition & Biosciences USA 1, LLC Verfahren zur rückgewinnung eines veresterten celluloseethers aus einem reaktionsproduktgemisch
WO2018170083A1 (en) 2017-03-17 2018-09-20 Dow Global Technologies Llc Process for recovering an esterified cellulose ether from a reaction product mixture
CR20200378A (es) 2018-03-14 2021-01-08 Janssen Sciences Ireland Unlimited Co Régimen posológico del modulador del emsalblaje de la cápside
WO2019220282A1 (en) * 2018-05-14 2019-11-21 Capsugel Belgium Nv Solid dosage forms with high active agent loading
WO2020117736A1 (en) 2018-12-04 2020-06-11 DDP Specialty Electronic Materials US, Inc. Hydroxypropyl methylcellulose acetate succinates of very high molecular weight
WO2020131785A1 (en) * 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxypropyl methylcellulose acetate succinate
WO2020131801A1 (en) * 2018-12-18 2020-06-25 DDP Specialty Electronic Materials US, Inc. A sustained release composition comprising a hydroxypropyl methylcellulose acetate succinate
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
EP4073167A1 (de) 2019-12-09 2022-10-19 Nutrition & Biosciences USA 1, LLC Zusammensetzung mit einer hochsubstituierten hydroxypropylmethylcellulose und einem zuckeralkohol
WO2021118915A1 (en) 2019-12-09 2021-06-17 Nutrition & Biosciences Usa 1, Llc Hydroxypropyl alkyl cellulose acetate succinate heteropolymers
IL294928A (en) 2020-01-24 2022-09-01 Nanocopoeia Llc Amorphous solid dispersions of dasatinib and uses thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP2024520798A (ja) * 2021-06-09 2024-05-24 ロンザ・ベンド・インコーポレーテッド 非晶質固体分散体の調製のための噴霧乾燥のための混合溶媒
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226981A (en) * 1977-09-28 1980-10-07 Shin-Etsu Chemical Co., Ltd. Ether-ester derivatives of cellulose and their applications
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
JP3149122B2 (ja) 1994-11-07 2001-03-26 信越化学工業株式会社 固形腸溶製剤のコーティング用基剤
JP3149125B2 (ja) * 1995-05-01 2001-03-26 信越化学工業株式会社 固形腸溶製剤のコーティング用基剤
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
EP1970052A2 (de) * 1999-02-09 2008-09-17 Pfizer Products Inc. Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
AU2002212102A1 (en) * 2000-11-08 2002-05-21 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
TNSN03137A1 (en) * 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
KR100664822B1 (ko) 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
AR046811A1 (es) 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
WO2005102092A1 (ja) 2004-04-20 2005-11-03 Urban-Nawachi Co., Ltd 靴構造の履物

Also Published As

Publication number Publication date
CA2568007A1 (en) 2005-12-08
WO2005115330A2 (en) 2005-12-08
EP1753402B1 (de) 2008-10-01
JP2008501009A (ja) 2008-01-17
MXPA06013891A (es) 2007-01-26
EP1753402A2 (de) 2007-02-21
US20080262107A1 (en) 2008-10-23
US8207232B2 (en) 2012-06-26
US20120264833A1 (en) 2012-10-18
WO2005115330A3 (en) 2006-07-06
US8940800B2 (en) 2015-01-27
ATE409462T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
ATE409462T1 (de) Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
MX2012014849A (es) Acetato succinato de hidroxipropil metil celulosa con substitucion de acetato de y succinato intensificada.
ATE444060T1 (de) Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
AR048331A1 (es) Sistema de administracion de farmacos con retencion gastrica
CY1112268T1 (el) Σκευασμα δισκιου παρατεταμενης αποδεσμευσης περιεχον πραμιπεξολη ή ενα φαρμακευτικως αποδεκτο αλας αυτης
ATE361758T1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
ATE412387T1 (de) Medizinische vorrichtungen
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
ATE432919T1 (de) Azetidinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
WO2006024944A3 (en) Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
ATE288256T1 (de) Dermale zusammensetzungen
DK1543063T3 (da) Medikament levering
RS52633B (en) CANCER TREATMENT FORMULATION
DE602007002295D1 (de) Arzneimittelabgabevorrichtung
NO20064570L (no) Farmasoytiske preparater
NO20053556D0 (no) Polymerkonjugater av interferon-beta med forbedret biologisk potens.
BR0113663A (pt) Composições de pelìcula de pectina
DE60026357D1 (de) An- und abschwellende polymermischungen
AP2002002558A0 (en) Pharmaceutical compositions containing polymer and drug assemblies.
ATE554751T1 (de) Nanopartikel mit einem nicht ionisierbaren polymer und einem anionischen zellulosepolymer
DK1480679T3 (da) Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
BRPI0607413A2 (pt) composição farmacêutica compreendendo derivados de indolilmaleimida
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
DE602004031767D1 (de) Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee